FTPI SYT-SSX1 inhibitor RGNCY-0092
Per 10 mg
FTPI is selectively cytotoxic in synovial sarcoma cell lines (Yamato IC50 = 33µM and ASKA IC50 = 39µM). Cell cycle analysis shows and involvement of an apoptotic mechanism of cell death. FTPI treatment down regulates SYT-SSX1 and modulates its downstream target genes. This results in the down regulation of oncogenes involved in EMT such as beta-catenin, PDGFRA, Cyclin D1, Frizzle receptor and EGFR. Data suggests that FTPI is a potential anti-cancer molecule.
Systematic Name: 6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
Molecular Weight: 366.41
Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy. Valliyammi, N et al. J. Med. Chem. 2018, 61, 8754−8773.
There are no uploaded files